FindOut Diagnostic
Diagnostic self-tests for proactive health management, certified ISO 13485:2016.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| SEK | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 10 % | (21 %) | 37 % | 27 % | 494 % | (79 %) | (5 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 81 % | (71 %) | (63 %) | (233 %) | (36 %) | (1659 %) | (2133 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
FindOut Diagnostic AB develops, manufactures and distributes in vitro diagnostic (IVD) self tests to the European market.
FindOut has developed a mobile application and use neural networks that will take self-tests to a new level. With a drop of blood, an immunoassay lateral flow test and the app, individuals will get access to more health data than ever before. The first product with the novel technology is in the field of infection. With the neural networks as the basis, the app will be scaled to other areas for in-vitro diagnostics.
Current product is the market leading FindOut Celiac Test (gluten sensitive) which is being distributed to the Swedish and Norwegian pharmacies.